Stockscreener 앱 받기
156.13
0.27%
-0.42
시간 외 거래:
156.00
-0.13
-0.08%
전일 마감가:
$156.55
열려 있는:
$156.55
하루 거래량:
109.81K
Relative Volume:
0.44
시가총액:
$2.25B
수익:
$1.30M
순이익/손실:
$-49.30M
주가수익비율:
-37.45
EPS:
-4.1688
순현금흐름:
$-29.10M
1주 성능:
-1.04%
1개월 성능:
+4.31%
6개월 성능:
+91.48%
1년 성능:
+238.68%
1일 변동 폭
$154.35
$160.33
1주일 범위
$150.41
$160.33
52주 변동 폭
$44.24
$161.38
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
156.13 | 2.23B | 1.30M | -49.30M | -29.10M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Mizuho | Outperform |
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - marketbeat.com
PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Therapeutics Inc (PVLA) - GuruFocus
Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada
Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Australia
Palvella Therapeutics, Inc. (PVLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company - marketbeat.com
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Yahoo Finance
Jennison Associates Expands Palvella Therapeutics (PVLA) Stake i - GuruFocus
Palvella Therapeutics Inc (PVLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Q3 EPS Estimate for Palvella Therapeutics Cut by Analyst - marketbeat.com
Truist Financial Sticks to Its Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
High-Risk Warning for Investors in Palvella Therapeutics Securities - The Globe and Mail
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call - Sahm
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270 - moomoo.com
Palvella Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PVLA) 2026-08-05 - Seeking Alpha
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207 - moomoo.com
Palvella details QTORIN progress and Nasdaq uplisting milestones - The Globe and Mail
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ... - finance.yahoo.com
Palvella Therapeutics Q2 Earnings Call Highlights - MarketBeat
Palvella Therapeutics, Inc.Common Stock (PVLA) Stock Price, News, Quote & History - FinancialContent
Earnings call transcript: Palvella shares rise on q2 2026 launch progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS - marketbeat.com
PVLA: Positive phase III data, rolling NDA, and strong cash position drive launch readiness and pipeline growth - TradingView
PVLA: QTORIN rapamycin advanced toward FDA approval with strong phase III data, robust cash, and launch readiness - TradingView
Palvella Therapeutics Q2 Net Loss Widens - marketscreener.com
Palvella Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palvella Therapeutics, Inc. (PVLA) Q2 FY2026 earnings call transcript - Yahoo Finance
Palvella Therapeutics Q2 net loss widens on higher expenses - TradingView
PVLA: Advanced NDA submission and clinical pipeline with $250.6M cash; net loss widened to $21.9M - TradingView
Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss - marketscreener.com
Palvella Therapeutics: Q2 Earnings Snapshot - Barchart.com
Palvella Reports Q2 Net Loss and Advances QTORIN NDA Plans - Quiver Quantitative
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
All eyes on Palvella earnings as rare disease drug nears approval - Investing.com Nigeria
Arete Wealth Advisors LLC Makes New $2.18 Million Investment in Palvella Therapeutics, Inc. $PVLA - marketbeat.com
Palvella Therapeutics Inc (PVLA) Institutional Confidence - TradingKey
Palvella Therapeutics Chief Scientific Officer Jeff - GlobeNewswire
Palvella Scientist Set to Discuss Reusing Approved Drugs at FDA - Stock Titan
Palvella Therapeutics (PVLA) Holds Steady Near Key Resistance LevelDelta Hedging - dars.gov.et
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 - markets.businessinsider.com
Palvella Therapeutics to Host Second Quarter 2026 Financial - GlobeNewswire
Palvella Therapeutics Inc (PVLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palvella Therapeutics to report Q2 2026 results on August 4 - scanx.trade
Palvella Therapeutics Inc (PVLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Palvella Therapeutics Market Sentiment - Benzinga España
Palvella Therapeutics Inc (PVLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palvella Therapeutics Inc (PVLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):